• 1
    Terakawa T, Miyake H, Tanaka K, Takenaka A, Inoue TA, Fujisawa M. Surgical margin status of open versus laparoscopic radical prostatectomy specimens. Int. J. Urol. 2008; 15: 7047.
  • 2
    Hara I, Kawabata G, Tanaka K et al. Oncological outcome of laparoscopic prostatectomy. Int. J. Urol. 2007; 14: 51520.
  • 3
    Schmeller N, Keller H, Janetschek G. Head-to-head comparison of retropubic, perineal and laparoscopic radical prostatectomy. Int. J. Urol. 2007; 14: 4025.
  • 4
    Webster TM, Herrell SD, Chang SS et al. Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: A prospective assessment of postoperative pain. J. Urol. 2005; 174: 91214, discussion 14.
  • 5
    Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL. Utilization and outcomes of minimally invasive radical prostatectomy. J. Clin. Oncol. 2008; 26: 227884.
  • 6
    Ahlering TE, Skarecky D, Lee D, Clayman RV. Successful transfer of open surgical skills to a laparoscopic environment using a robotic interface: Initial experience with laparoscopic radical prostatectomy. J. Urol. 2003; 170: 173841.
  • 7
    Herrell SD, Smith JA Jr. Robotic-assisted laparoscopic prostatectomy: What is the learning curve? Urology 2005; 66: 1057.
  • 8
    Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N. Engl. J. Med. 2002; 346: 113844.
  • 9
    Eastham JA, Kattan MW, Riedel E et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J. Urol. 2003; 170: 22925.
  • 10
    Vickers AJ, Bianco FJ, Serio AM et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J. Natl. Cancer Inst. 2007; 99: 11717.
  • 11
    Walsh PC. Anatomic radical prostatectomy: Evolution of the surgical technique. J. Urol. 1998; 160: 241824.
  • 12
    Eastham JA. Surgery insight: Optimizing open nerve-sparing radical prostatectomy techniques for improved outcomes. Nat. Clin. Pract. Urol. 2007; 4: 5619.
  • 13
    Eastham JA, Scardino PT. Radical prostatectomy for clinical stage T1 and T2 prostate cancer. In: VogelzangNJ, ScardinoPT, ShipleyWU, CoffeyDF (eds). Comprehensive Textbook of Genitourinary Oncology, 3rd edn. Baltimore, MD: Lippincott Williams and Wilkins, 2005; 16689.
  • 14
    Walsh PC, Donker PJ. Impotence following radical prostatectomy: Insight into etiology and prevention. J. Urol. 1982; 128: 4927.
  • 15
    Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: Influence of preservation of neurovascular bundles. J. Urol. 1991; 145: 9981002.
  • 16
    Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J. Urol. 2000; 164: 192934.
  • 17
    Eichelberg C, Erbersdobler A, Michl U et al. Nerve distribution along the prostatic capsule. Eur. Urol. 2007; 51: 10510, discussion 10–1.
  • 18
    Costello AJ, Brooks M, Cole OJ. Anatomical studies of the neurovascular bundle and cavernosal nerves. BJU Int. 2004; 94: 10716.
  • 19
    Lunacek A, Schwentner C, Fritsch H, Bartsch G, Strasser H. Anatomical radical retropubic prostatectomy: ‘Curtain dissection’ of the neurovascular bundle. BJU Int. 2005; 95: 122631.
  • 20
    Graefen M, Walz J, Huland H. Open retropubic nerve-sparing radical prostatectomy. Eur. Urol. 2006; 49: 3848.
  • 21
    Montorsi F, Salonia A, Suardi N et al. Improving the preservation of the urethral sphincter and neurovascular bundles during open radical retropubic prostatectomy. Eur. Urol. 2005; 48: 93845.
  • 22
    Kaul S, Bhandari A, Hemal A, Savera A, Shrivastava A, Menon M. Robotic radical prostatectomy with preservation of the prostatic fascia: A feasibility study. Urology 2005; 66: 12615.
  • 23
    Nielsen ME, Marschke P, Walsh PC. High anterior release of the levator fascia improves sexual function following open radical retropubic prostatectomy. American Urological Association Annual Meeting, Orlando, FL, 2008.
  • 24
    Sofer M, Hamilton-Nelson KL, Civantos F, Soloway MS. Positive surgical margins after radical retropubic prostatectomy: The influence of site and number on progression. J. Urol. 2002; 167: 24536.
  • 25
    Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J. Urol. 2004; 172: 132832.
  • 26
    Ates M, Teber D, Gozen AS et al. Do tumor volume, tumor volume ratio, type of nerve sparing and surgical experience affect prostate specific antigen recurrence after laparoscopic radical prostatectomy? A matched pair analysis. J. Urol. 2007; 177: 17715, discussion 1775–6.
  • 27
    Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J. Urol. 1994; 152: 18316.
  • 28
    Gao X, Mohideen N, Flanigan RC, Waters WB, Wojcik EM, Leman CR. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: Implications for treatment selection. J. Urol. 2000; 164: 19826.
  • 29
    Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 8438.
  • 30
    Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J. Urol. 2004; 171: 10937.
  • 31
    Tsuzuki T, Hernandez DJ, Aydin H, Trock B, Walsh PC, Epstein JI. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. J. Urol. 2005; 173: 4503.
  • 32
    Menon M, Shrivastava A, Kaul S et al. Vattikuti Institute prostatectomy: Contemporary technique and analysis of results. Eur. Urol. 2007; 51: 64857, discussion 57–8.
  • 33
    Masterson TA, Serio AM, Mulhall JP, Vickers AJ, Eastham JA. Modified technique for neurovascular bundle preservation during radical prostatectomy: Association between technique and recovery of erectile function. BJU Int. 2008; 101: 121722.
  • 34
    Kane CJ, Presti JC Jr, Amling CL et al. Changing nature of high risk patients undergoing radical prostatectomy. J. Urol. 2007; 177: 11317.
  • 35
    Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: Results from cancer of the prostate strategic urological research endeavor (CaPSURE). J. Urol. 2005; 173: 155761.
  • 36
    Denberg TD, Glode LM, Steiner JF, Crawford ED, Hoffman RM. Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU Int. 2006; 98: 33540.
  • 37
    Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J. Clin. Oncol. 2005; 23: 814651.
  • 38
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005; 95: 7516.
  • 39
    Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur. Urol. 1997; 32: 38590.
  • 40
    Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001; 57: 2815.
  • 41
    Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 113842.
  • 42
    Donohue JF, Bianco FJ Jr, Kuroiwa K et al. Poorly differentiated prostate cancer treated with radical prostatectomy: Long-term outcome and incidence of pathological downgrading. J. Urol. 2006; 176: 9915.
  • 43
    Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: Influence of concomitant pathological variables. J. Urol. 2002; 167: 11722.
  • 44
    D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 96974.
  • 45
    Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 2007; 177: 210631.
  • 46
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist. J. Natl. Cancer Inst. 2006; 98: 83945.
  • 47
    Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 2006; 107: 2597603.
  • 48
    Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 4339.
  • 49
    Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095101.
  • 50
    Berglund RK, Jones JS, Ulchaker JC et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis. Urology 2006; 67: 12536.
  • 51
    Yossepowitch O, Eggener SE, Bianco FJ Jr et al. Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods. J. Urol. 2007; 178: 4939, discussion 499.
  • 52
    Yossepowitch O, Eggener SE, Serio AM et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur. Urol. 2008; 53: 9509.
  • 53
    Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J. Urol. 2003; 169: 84954.
  • 54
    Daneshmand S, Quek ML, Stein JP et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J. Urol. 2004; 172: 22525.
  • 55
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 1999; 341: 17818.
  • 56
    Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer. J. Urol. 2004; 172: 18404.
  • 57
    Touijer K, Rabbani F, Otero JR et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J. Urol. 2007; 178: 1204.